Spike Protein News and Research

RSS

Coronaviruses represent a source of pandemic viruses

In a new paper published on the preprint journal bioRxiv in April 2020, researcher T. Konishi argues that the coronavirus family is a constellation of pandemic pathogens, that includes the currently spreading severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

29 Apr 2020

Dominant SARS-CoV-2 strain A2a binds more easily to ACE2 receptors

The COVID-19 pandemic has affected almost all countries across the world, and India is no exception. Researchers have found that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has undergone several mutations with time.

28 Apr 2020

Research on SARS-CoV-2 spike protein may lead to new vaccines and treatments

The virus that causes COVID-19 is studded on its exterior with "spike proteins," a key component in its ability to infect human cells. Two University of Georgia researchers, Rob Woods and Parastoo Azadi, are investigating the proteins and sugars on the surface of the virus with the goal of finding information that could lead to vaccines and therapeutics.

28 Apr 2020

SARS-CoV-2 spike protein discovery could pave way for COVID-19 vaccine

Researchers at the Indian Institute of Technology, Guwahati, have made an important discovery about a viral fusion protein found on the surface of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could help researchers develop a vaccine.

27 Apr 2020

Recombinant protein produces neutralizing COVID-19 antibodies in primate model

A new study reports the induction of high levels of neutralizing antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus causing the current pandemic of COVID-19. This promising finding was reported on the preprint server bioRxiv on April 2020.

26 Apr 2020

FAU scientists aim to develop a passive vaccine against COVID-19

Nothing less than the development of a passive vaccine against Covid-19 has been undertaken by a team of scientists from Friedrich-Alexander-Universität Erlangen-Nürnberg, Universitätsklinkum Erlangen and their partners from the Fraunhofer Institute for Cell Therapy and Immunology in Leipzig and the German Primate Centre in Göttingen.

24 Apr 2020

Goblet cells in the human nasal passage may play key role in enabling COVID-19 infections

Two significant international studies involving hundreds of scientists, including a human geneticist at the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, suggest that specific cells in the human nasal passage shaped like a champagne glass, known as goblet cells, may play a significant role in enabling COVID-19 infections.

24 Apr 2020

Scientists are developing synthetic COVID-19 antibody to treat sick patients

A team of researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with GenScript, is developing a synthetic antibody to SARS-CoV-2, the virus that causes coronavirus disease (COVID-19). This antibody is intended to block the virus from entering human lung cells, and would be another potential treatment option for COVID-19.

24 Apr 2020

SARS-CoV-2 targets specific cells in the lung, nasal passage, and intestine

Now, the researchers from the Massachusetts Institute of Technology (MIT) have identified specific types of cells that are targets of the SARS-CoV-2 that causes the COVID-19 pandemic. The findings of the study published in the journal Cell may help in developing novel therapeutics to combat the deadly viral infection.

23 Apr 2020

RAS inhibitors and COVID-19 severity in hypertensive patients

A new study published in the journal JAMA Cardiology in April 2020 reports that patients with hypertension who are taking medications called ACE inhibitors (ACEI) or ARBs are not at higher risk for death or more severe illness with COVID-19. This conclusion supports current guidelines for the treatment of hypertension during this pandemic.

23 Apr 2020

Ablexis, AlivaMab Discovery Services, and Berkeley Lights Collaborate to Identify a Diverse Panel of Anti-SARS-CoV-2 Human Antibodies

Ablexis, LLC, ADS, and Berkeley Lights, Inc. today announced the generation and recovery of sequences against the S1 spike protein of the SARS-CoV-2 virus.

From Bruker Cellular Analysis 23 Apr 2020

Scientists identify cells likely targeted by novel coronavirus

Researchers at MIT; the Ragon Institute of MGH, MIT, and Harvard; and the Broad Institute of MIT and Harvard; along with colleagues from around the world have identified specific types of cells that appear to be targets of the coronavirus that is causing the Covid-19 pandemic.

22 Apr 2020

A first-in-human trial with promising MERS coronavirus vaccine

Over the past 20 years, coronaviruses have been responsible for large outbreaks, resulting in severe respiratory illness and a number of deaths.

22 Apr 2020

USPTO grants patent to TAU scientist for innovative coronavirus vaccine design

Researchers worldwide are racing at breakneck speed to develop potential vaccines and drugs to fight the novel coronavirus, SARS-Cov-2.

21 Apr 2020

Do ACE inhibitors increase SARS-CoV-2 binding to ACE2?

The COVID-19 pandemic has forced clinicians and academicians to intensive research to find evidence for many conventional therapies. A new round-up editorial published in the journal Cardiovascular Research in April 2020 summarizes the current clinical grounds for and against the use of the commonly used angiotensin axis inhibitors in patients with COVID-19.

20 Apr 2020

New biosensor rapidly detects SARS-CoV-2 from nasopharyngeal swabs

According to many experts, early diagnosis and management are critical for slowing the spread of SARS-CoV-2, the new coronavirus that causes COVID-19.

20 Apr 2020

Novel coronavirus mutation could spell trouble for vaccine development

New research shows that the novel coronavirus is undergoing mutations that could make it challenging to develop a vaccine against. There are a few vaccine candidates that are in the making to prevent COVID-19. With a potential for mutation, the vaccines that are being developed now may not work against the emergent mutated strains worry Taiwanese and Australian researchers. The study is titled, “Analysis of the mutation dynamics of SARS-CoV-2 reveals the spread history and emergence of 2 RBD mutant with lower ACE2 binding affinity.”

19 Apr 2020

Researchers design peptide inhibitors for potential COVID-19 treatments

Scientists across the globe are rushing to find inhibitors of SARS-CoV-2, the new coronavirus behind the COVID-19 pandemic.

16 Apr 2020

Anosmia (loss of smell) confirmed as a clinical feature of COVID-19

Earlier last month, the association of ear, nose, and throat (ENT) specialists in the UK issued a public statement advising patients with a sudden loss of smell or taste to get tested for COVID-19. They cited not only their own observations but those from numerous other ENT consultants the world around. A review of multiple papers on the sinus and nasal symptoms and signs related to the diagnosis of COVID-19, published in April 2020, in the journal Laryngoscope Investigative Otolaryngology, reiterates this finding.

15 Apr 2020

ACE2 genetic variants may influence coronavirus disease progression

Researchers in British Columbia have identified a set of gene variants that are likely to influence disease progression from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection to COVID-19 disease.

15 Apr 2020